55 related articles for article (PubMed ID: 15807491)
1. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
[TBL] [Abstract][Full Text] [Related]
2. Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance.
Khan SN; Persons JD; Paulsen JL; Guerrero M; Schiffer CA; Kurt-Yilmaz N; Ishima R
Biochemistry; 2018 Mar; 57(10):1652-1662. PubMed ID: 29457713
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug.
Jayaswal A; Mishra A; Mishra H; Shah K
Bioinformation; 2014; 10(4):227-32. PubMed ID: 24966525
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Reasons for Decrease in Binding Affinity of HIV-2 Against HIV-1 Protease Complex Using Interaction Entropy Under Polarized Force Field.
Cong Y; Li Y; Jin K; Zhong S; Zhang JZH; Li H; Duan L
Front Chem; 2018; 6():380. PubMed ID: 30197882
[TBL] [Abstract][Full Text] [Related]
5. Modulation of HIV protease flexibility by the T80N mutation.
Zhou H; Li S; Badger J; Nalivaika E; Cai Y; Foulkes-Murzycki J; Schiffer C; Makowski L
Proteins; 2015 Nov; 83(11):1929-39. PubMed ID: 25488402
[TBL] [Abstract][Full Text] [Related]
6. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding.
Young T; Abel R; Kim B; Berne BJ; Friesner RA
Proc Natl Acad Sci U S A; 2007 Jan; 104(3):808-13. PubMed ID: 17204562
[TBL] [Abstract][Full Text] [Related]
7. Automated clustering of probe molecules from solvent mapping of protein surfaces: new algorithms applied to hot-spot mapping and structure-based drug design.
Lerner MG; Meagher KL; Carlson HA
J Comput Aided Mol Des; 2008 Oct; 22(10):727-36. PubMed ID: 18679808
[TBL] [Abstract][Full Text] [Related]
8. Designing Fluorescent Peptide Sensors with Dual Specificity for the Detection of HIV-1 Protease.
Herpoldt KL; Artzy-Schnirman A; Christofferson AJ; Makarucha AJ; de la Rica R; Yarovsky I; Stevens MM
Chem Mater; 2015 Oct; 27(20):7187-7195. PubMed ID: 28479671
[TBL] [Abstract][Full Text] [Related]
9. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
Saen-oon S; Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Hannongbua S
J Mol Graph Model; 2007 Nov; 26(4):720-7. PubMed ID: 17543558
[TBL] [Abstract][Full Text] [Related]
10. Examination of HIV-1 protease secondary structure specificity using conformationally constrained inhibitors.
Kahn M; Nakanishi H; Chrusciel RA; Fitzpatrick D; Johnson ME
J Med Chem; 1991 Dec; 34(12):3395-9. PubMed ID: 1766005
[No Abstract] [Full Text] [Related]
11. Conformational flexibility in the flap domains of ligand-free HIV protease.
Heaslet H; Rosenfeld R; Giffin M; Lin YC; Tam K; Torbett BE; Elder JH; McRee DE; Stout CD
Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513
[TBL] [Abstract][Full Text] [Related]
12. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes.
Lapatto R; Blundell T; Hemmings A; Overington J; Wilderspin A; Wood S; Merson JR; Whittle PJ; Danley DE; Geoghegan KF
Nature; 1989 Nov; 342(6247):299-302. PubMed ID: 2682266
[TBL] [Abstract][Full Text] [Related]
13. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
Tie Y; Kovalevsky AY; Boross P; Wang YF; Ghosh AK; Tozser J; Harrison RW; Weber IT
Proteins; 2007 Apr; 67(1):232-42. PubMed ID: 17243183
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HIV protease binding pockets based on 3D shape and electrostatic potential descriptors.
Reddy AS; Jalahalli V; Kumar S; Garg R; Zhang X; Sastry GN
Chem Biol Drug Des; 2011 Feb; 77(2):137-51. PubMed ID: 21266017
[TBL] [Abstract][Full Text] [Related]
15. The effect of depression on quality of life of patients with type II diabetes mellitus.
Eren I; Erdi O; Sahin M
Depress Anxiety; 2008; 25(2):98-106. PubMed ID: 17311266
[TBL] [Abstract][Full Text] [Related]
16. Impact of depression on health related quality of life in patients with diabetes.
Verma SK; Luo N; Subramaniam M; Sum CF; Stahl D; Liow PH; Chong SA
Ann Acad Med Singap; 2010 Dec; 39(12):913-7. PubMed ID: 21274488
[TBL] [Abstract][Full Text] [Related]
17. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
Connolly KR; Thase ME
Drugs; 2011 Jan; 71(1):43-64. PubMed ID: 21175239
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in depression scale (QLDS). Development, reliability, validity, responsiveness and application.
Tuynman-Qua H; de Jonghe F; McKenna SP
Eur Psychiatry; 1997; 12(4):199-202. PubMed ID: 19698532
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
20. Anxiety, depression, and quality of life in primary care patients.
Brenes GA
Prim Care Companion J Clin Psychiatry; 2007; 9(6):437-43. PubMed ID: 18185823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
